Drug Abuse Treatment Market to Surpass US$ 26.3 Bn Threshold by 2026


Posted March 27, 2019 by VedantR

Mylan N.V. launched its new drugs Disulfiram Tablets USP, 250 mg and 500 mg in the U.S. market, drugs Disulfiram Tablets USP is a generic version of Odyssey Pharmaceutical's Antabuse.

 
For instance, in 2015, Mylan N.V. launched its new drugs Disulfiram Tablets USP, 250 mg and 500 mg in the U.S. market, drugs Disulfiram Tablets USP is a generic version of Odyssey Pharmaceutical's Antabuse. In 2017, Glenmark Pharmaceuticals launched its new nicotine replacement therapy namely Kwitz in India. Kwitz is a nicotine gum and is available in two variants Kwitz 2 mg and Kwitz 4 mg. Kwitz 2 mg is for the smokers having less than 20 cigarettes per day and Kwitz 4 mg is for those who smoke more than 20 cigarettes per day.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2011

In April 2018, Lil' Drug Store Products Inc. launched its Nicotac brand nicotine gum in market. Lil' Drug Store Products Inc. has launched its Nicotac in two nicotine strengths (2 mg and 4 mg nicotine polarcrilex). In 2017, Cipla Health, an arm of Cipla Limited launched a new Nicotex Nicotine Patches. Nicotex Nicotine Patches are skin/transdermal patches, which helps to quit smoking in 12 months. Company has launched its patches in 3 strengths 21 mg, 14 mg, and 7 mg. 21 mg patch is for one who smoke more than 20 cigarette a day, 14 mg is for those who smoke less that 20 cigarette a day

Furthermore, increasing prevalence of drug abuse and dependence in key regions are expected to increase the demand for its treatment and management drugs in near future. For instance, according to the Substance Abuse and Mental Health Services Administration (SAMHSA), around 830,000 people in the U.S. used heroin in 2015, which is more than double the number from 2002. Such increasing rates of drugs abuse are expected to fuel growth of the global drug abuse treatment market in near future.

Frequent product launches, approvals, and robust pipeline of novel products are expected to be the major driver for growth of the global drug abuse treatment market over forecast period. For instance, in April 2018, Lil' Drug Store Products Inc. launched its Nicotac brand nicotine gum in the market. Lil' Drug Store Products Inc. has launched its Nicotac in two nicotine strengths (2MG and 4MG nicotine polarcrilex). Furthermore, the increasing prevalence of drug abuse is expected to increase the demand for its treatment drugs which in turn is expected to fuel global drug abuse treatment market growth. For instance, according to the data published by World Health Organization (WHO) in 2018, around 7 million people die worldwide annually due to tobacco abuse.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2011

Key players operating in the drug abuse treatment market include Cipla Limited, Glenmark Pharmaceuticals, Pfizer Inc., Mylan N.V., Odyssey Pharmaceuticals Inc., Lil' Drug Store Products Inc., Indivior Plc., Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., and British American Tobacco Plc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr.Shah
Phone 12067016702
Business Address 1001 4th Ave,
#3200
Country United States
Categories Advertising , Business , Industry
Tags Drug Abuse Treatment Market, , drug abuse treatment market size, , drug abuse treatment market analysis,
Last Updated March 27, 2019
Loading...